JP2014040441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014040441A5 JP2014040441A5 JP2013201931A JP2013201931A JP2014040441A5 JP 2014040441 A5 JP2014040441 A5 JP 2014040441A5 JP 2013201931 A JP2013201931 A JP 2013201931A JP 2013201931 A JP2013201931 A JP 2013201931A JP 2014040441 A5 JP2014040441 A5 JP 2014040441A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptibody
- buffer
- composition
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79399706P | 2006-04-21 | 2006-04-21 | |
| US60/793,997 | 2006-04-21 | ||
| US11/788,697 | 2007-04-19 | ||
| US11/788,697 US9283260B2 (en) | 2006-04-21 | 2007-04-19 | Lyophilized therapeutic peptibody formulations |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506615A Division JP5432705B2 (ja) | 2006-04-21 | 2007-04-20 | 凍結乾燥された治療用ペプチボディ製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015208065A Division JP6356106B2 (ja) | 2006-04-21 | 2015-10-22 | 凍結乾燥された治療用ペプチボディ製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014040441A JP2014040441A (ja) | 2014-03-06 |
| JP2014040441A5 true JP2014040441A5 (https=) | 2014-06-19 |
| JP5873854B2 JP5873854B2 (ja) | 2016-03-01 |
Family
ID=38625630
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506615A Active JP5432705B2 (ja) | 2006-04-21 | 2007-04-20 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2013201931A Active JP5873854B2 (ja) | 2006-04-21 | 2013-09-27 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2015208065A Active JP6356106B2 (ja) | 2006-04-21 | 2015-10-22 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2018111720A Active JP6787953B2 (ja) | 2006-04-21 | 2018-06-12 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2020128961A Pending JP2021006525A (ja) | 2006-04-21 | 2020-07-30 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2022130437A Pending JP2022166219A (ja) | 2006-04-21 | 2022-08-18 | 凍結乾燥された治療用ペプチボディ製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506615A Active JP5432705B2 (ja) | 2006-04-21 | 2007-04-20 | 凍結乾燥された治療用ペプチボディ製剤 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015208065A Active JP6356106B2 (ja) | 2006-04-21 | 2015-10-22 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2018111720A Active JP6787953B2 (ja) | 2006-04-21 | 2018-06-12 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2020128961A Pending JP2021006525A (ja) | 2006-04-21 | 2020-07-30 | 凍結乾燥された治療用ペプチボディ製剤 |
| JP2022130437A Pending JP2022166219A (ja) | 2006-04-21 | 2022-08-18 | 凍結乾燥された治療用ペプチボディ製剤 |
Country Status (38)
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1783222E (pt) | 1998-10-23 | 2012-07-26 | Kirin Amgen Inc | Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| EP2921180B1 (en) | 1999-02-22 | 2019-08-14 | University of Connecticut | Albumin-free factor VIII formulations |
| IL146508A0 (en) | 1999-06-01 | 2002-07-25 | Biogen Inc | A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
| GEP20074252B (en) | 2001-04-13 | 2007-12-10 | Biogen Idec Inc | Antibodies to vla-1 |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| CA2822302A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Methods of impairing osteoclast differentiation |
| KR101191322B1 (ko) | 2006-04-07 | 2012-10-16 | 메리온 리서치 Ⅲ 리미티드 | 증진제를 함유하는 고형 경구용 투여 제형 |
| AU2011265555B2 (en) * | 2006-04-21 | 2016-03-10 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| MX2008014793A (es) | 2006-05-25 | 2008-12-02 | Biogen Idec Inc | Metodos para tratar la apoplejia. |
| CN107096012A (zh) | 2008-05-07 | 2017-08-29 | 诺和诺德股份有限公司 | 肽的组合物及其制备方法 |
| NZ593190A (en) | 2008-11-07 | 2013-01-25 | Baxter Int | Factor viii formulations |
| CA3040973A1 (en) * | 2008-12-16 | 2010-07-01 | Genzyme Corporation | Oligosaccharide-protein conjugates |
| US20120183546A1 (en) | 2009-09-23 | 2012-07-19 | Amgen Inc. | Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane |
| KR101335765B1 (ko) * | 2010-01-19 | 2013-12-02 | 한미사이언스 주식회사 | 지속형 에리스로포이에틴 결합체의 액상 제제 |
| WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| AU2011336413B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
| MX349294B (es) | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Formulaciones virales liofilizadas. |
| JP5759211B2 (ja) * | 2011-03-11 | 2015-08-05 | 三洋化成工業株式会社 | 凍結乾燥方法 |
| MX358726B (es) | 2011-06-29 | 2018-09-03 | Amgen Inc | Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales. |
| DE102011055889B4 (de) * | 2011-11-30 | 2013-08-01 | Otc Gmbh | Verfahren zur Herstellung eines Protein-Hydrolysates |
| CN102586217A (zh) * | 2011-12-16 | 2012-07-18 | 深圳市海普瑞药业股份有限公司 | 肝素黄杆菌肝素酶ⅰ、ⅱ、ⅲ的冻干保存方法 |
| RU2482128C1 (ru) * | 2011-12-28 | 2013-05-20 | Замертон Холдингс Лимитед | Пептиды, обладающие цитопротекторной активностью |
| CA2864539C (en) | 2012-02-16 | 2022-06-07 | Santarus, Inc. | Antibody formulations |
| EP2644186A1 (en) * | 2012-03-26 | 2013-10-02 | OTC GmbH | Hair conditioning composition for permanent and semi-permanent hair coloration applications |
| US20150335752A1 (en) * | 2012-06-25 | 2015-11-26 | Emergent Product Development Gaithersburg Inc. | Temperature Stable Vaccine Formulations |
| US9493562B2 (en) | 2012-07-19 | 2016-11-15 | Alethia Biotherapeutics Inc. | Anti-Siglec-15 antibodies |
| EP2698162A1 (en) * | 2012-08-15 | 2014-02-19 | Credentis AG | Method for producing a composition for treating a tooth lesion |
| US20160038588A1 (en) * | 2013-03-15 | 2016-02-11 | Amgen Inc. | Myostatin Antagonism in Human Subjects |
| CN104274827B (zh) * | 2013-07-01 | 2020-07-14 | 上海贺普药业股份有限公司 | 贺普拉肽的制剂 |
| WO2015035405A1 (en) * | 2013-09-09 | 2015-03-12 | Pinta Biotherapeutics, Inc. | Myostatin antagonist for treatment of pew in esrd patients |
| AU2014345802B2 (en) * | 2013-11-07 | 2018-01-25 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Storage stable lyophilized tripeptide formulations |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| US20160310584A1 (en) * | 2013-12-06 | 2016-10-27 | The Broad Institute Inc. | Formulations for neoplasia vaccines |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| WO2015100344A1 (en) | 2013-12-27 | 2015-07-02 | Emergent Product Development Gaithersburg Inc. | Temperature stable vaccine formulations |
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| US10918698B2 (en) * | 2014-03-29 | 2021-02-16 | Intas Pharmaceuticals Ltd. | Lyophilized pharmaceutical composition of Fc-peptide fusion protein |
| WO2015181756A1 (en) * | 2014-05-28 | 2015-12-03 | Nono Inc. | Chloride salt of tat-nr2b9c |
| KR20170035891A (ko) * | 2014-06-13 | 2017-03-31 | 산타 마리아 바이오테라퓨틱스, 인코포레이티드 | 제형화된 수용체 폴리펩타이드 및 관련 방법 |
| KR20250150675A (ko) * | 2014-08-20 | 2025-10-20 | 포톨라 파마슈티컬스, 인코포레이티드 | 인자 xa 해독제용 동결건조된 제형 |
| JP6671141B2 (ja) * | 2014-10-21 | 2020-03-25 | 大日本住友製薬株式会社 | 懸濁液剤 |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
| WO2016176427A1 (en) | 2015-04-30 | 2016-11-03 | Amgen Inc. | Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane |
| TW202523682A (zh) | 2015-05-20 | 2025-06-16 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
| WO2017106627A1 (en) | 2015-12-17 | 2017-06-22 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| LT3400019T (lt) | 2016-01-08 | 2022-12-12 | Ascendis Pharma Growth Disorders A/S | Cnp provaistai su prie žiedo fragmento prijungtu nešikliu |
| WO2017118707A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| NZ743487A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with increased nep stability |
| IL259827B2 (en) | 2016-01-08 | 2025-07-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low initial NPR-B activity |
| JP6992262B2 (ja) * | 2016-03-31 | 2022-02-15 | 東ソー株式会社 | 変性抗体測定試薬の製造方法 |
| KR102508650B1 (ko) | 2016-04-07 | 2023-03-13 | 더 존스 홉킨스 유니버시티 | 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법 |
| GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| WO2017197199A1 (en) * | 2016-05-13 | 2017-11-16 | Askgene Pharma Inc. | Novel angiopoietin 2, vegf dual antagonists |
| IL319473A (en) | 2016-12-02 | 2025-05-01 | Bioverativ Therapeutics Inc | Methods for treating hemophilic arthritis using chimeric blood clotting factors |
| WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| JP2017155046A (ja) * | 2017-04-05 | 2017-09-07 | イーストポンド・ラボラトリーズ・リミテッド | シクロデキストリンを含有する細胞水和組成物 |
| IL272513B2 (en) | 2017-09-15 | 2023-04-01 | Amgen Inc | Lyophilization process for pharmaceutical formulation of medical protein |
| MA50174A (fr) * | 2017-09-18 | 2020-07-29 | Amgen Inc | Formules de protéines de fusion vegfr-fc |
| KR102742284B1 (ko) * | 2017-12-22 | 2024-12-16 | 삼성바이오에피스 주식회사 | Vegf 길항제를 포함하는 액상 조성물 |
| CN108159413B (zh) * | 2018-01-10 | 2021-07-06 | 杭州洪桥中科基因技术有限公司 | 一种动物用冻干活疫苗及其制备方法 |
| GB201804835D0 (en) * | 2018-03-26 | 2018-05-09 | Ge Healthcare As | Formulation and method of preparation |
| BR112020022164A2 (pt) | 2018-05-18 | 2021-02-02 | Bioverativ Therapeutics Inc. | métodos de tratamento de hemofilia a |
| MA53333A (fr) * | 2018-07-31 | 2021-11-03 | Amgen Inc | Formulations pharmaceutiques d'anticorps masqués |
| EP3923906A1 (en) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| BR112021019612A2 (pt) * | 2019-04-01 | 2021-11-30 | Genentech Inc | Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa |
| EP3736574A1 (en) * | 2019-05-07 | 2020-11-11 | Atlas Antibodies AB | A formulation comprising an isotope labeled fusion polypeptide |
| EP3744319B1 (en) * | 2019-05-28 | 2022-10-19 | Ilkogen Ilac Sanayi Ve Ticaret A.S. | A stable lyophilized formulation for hybrid fc fused g-csf |
| JP2019178154A (ja) * | 2019-06-18 | 2019-10-17 | イーストポンド・ラボラトリーズ・リミテッド | シクロデキストリンを含有する細胞水和組成物 |
| GB201911461D0 (en) * | 2019-08-09 | 2019-09-25 | Arecor Ltd | Novel composition |
| US20220409627A1 (en) * | 2019-12-02 | 2022-12-29 | Altavant Sciences Gmbh | Treatment of lower airways disorders |
| US20230026969A1 (en) * | 2019-12-03 | 2023-01-26 | China Medical University | Oligopeptide, Testing Kit Thereof And Medical Composition Thereof |
| AU2020401160B2 (en) | 2019-12-10 | 2024-11-14 | Remegen Co., Ltd. | Pharmaceutical TACI-Fc fusion protein formulation |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
| CA3192030A1 (en) * | 2020-08-21 | 2022-02-24 | Resother Pharma A/S | Annexin a1 n-terminal peptide formulations and methods |
| WO2022206838A1 (en) * | 2021-03-31 | 2022-10-06 | Hangzhou Jiayin Biotech Ltd. | Fusion molecules targeting vegf and angiopoietin and uses thereof |
| CN118317787A (zh) | 2021-12-01 | 2024-07-09 | Ucb生物制药有限责任公司 | 包含Fab-PEG的制剂 |
| US20240076597A1 (en) * | 2022-09-02 | 2024-03-07 | Terumo Bct, Inc. | Methods for cell expansion, differentiation, and/or harvesting of natural killer cells using hollow-fiber membranes |
| WO2024133908A1 (en) * | 2022-12-23 | 2024-06-27 | Syna Therapeutics, S.L. | Stable pharmaceutical compositions comprising romiplostim |
| CN121925276A (zh) * | 2023-06-23 | 2026-04-24 | 密执安大学评议会 | 与肽相关的纳米颗粒组合物 |
| CN118126120B (zh) * | 2023-09-14 | 2024-12-06 | 海南大学 | 抑制Aβ42聚集并降低其细胞毒作用的三肽化合物 |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691016A (en) * | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) * | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US3941763A (en) * | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4195128A (en) * | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) * | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) * | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) * | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| DE3244265A1 (de) | 1982-11-30 | 1984-05-30 | Cassella Ag, 6000 Frankfurt | Weichmacheremulsion, verfahren zu ihrer herstellung und ihre anwendung |
| US4503235A (en) | 1983-03-11 | 1985-03-05 | Warner-Lambert Company | Process for producing 4-carbamoyl-1H-imidazolium-5-olate |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5089261A (en) * | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5627262A (en) | 1989-07-05 | 1997-05-06 | The Board Of Regents Of The University Of Oklahoma | Method and composition for the treatment of septic shock |
| ATE194384T1 (de) | 1989-09-12 | 2000-07-15 | Hoffmann La Roche | Tnf-bindende proteine |
| JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| DK0575545T3 (da) | 1991-03-15 | 2003-09-15 | Amgen Inc | Pegylering af polypeptider |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5281698A (en) * | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| US5362852A (en) * | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| US5733731A (en) * | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
| US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
| DE69334070T2 (de) | 1992-05-26 | 2007-01-04 | Immunex Corp., Thousand Oaks | Neue zytokine die cd30 binden |
| DE69332485T2 (de) | 1992-08-11 | 2003-11-13 | The President And Fellows Of Harvard College, Cambridge | Immunmodulierende peptide |
| GB9225448D0 (en) | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
| US5922545A (en) * | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
| US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| US5786331A (en) * | 1994-02-02 | 1998-07-28 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
| US5880096A (en) * | 1994-02-02 | 1999-03-09 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
| US5608035A (en) * | 1994-02-02 | 1997-03-04 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
| US5844929A (en) * | 1994-02-24 | 1998-12-01 | British Telecommunications Public Limited Company | Optical device with composite passive and tapered active waveguide regions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US20030053982A1 (en) * | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| AU693478B2 (en) | 1994-11-10 | 1998-07-02 | Metabolic Pharmaceuticals Limited | Treatment of obesity |
| IL116026A (en) | 1994-11-22 | 2005-08-31 | Rhone Poulenc Rorer Sa | Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses |
| US5888763A (en) | 1994-12-30 | 1999-03-30 | The Rockefeller University | Peptides specific for the first Crk-SH3 domain |
| JP2000510813A (ja) * | 1995-02-06 | 2000-08-22 | ジェネテイックス・インスティテュート・インコーポレイテッド | Ｉｌ−１２用処方 |
| IL113159A0 (en) | 1995-03-28 | 1995-06-29 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869451A (en) * | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
| CA2226575C (en) * | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US5746516A (en) | 1995-08-11 | 1998-05-05 | Hitachi Powdered Metals Co., Ltd. | Porous bearing system having internal grooves and electric motor provided with the same |
| US5817750A (en) | 1995-08-28 | 1998-10-06 | La Jolla Cancer Research Foundation | Structural mimics of RGD-binding sites |
| JPH09151200A (ja) | 1995-09-29 | 1997-06-10 | Ajinomoto Co Inc | ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤 |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| US5714577A (en) | 1996-01-26 | 1998-02-03 | University Of Pittsburgh | Antimicrobial peptides |
| IL117223A0 (en) | 1996-02-22 | 1996-06-18 | Yeda Res & Dev | Antipathogenic polypeptides and compositions comprising them |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| AU2597897A (en) | 1996-03-28 | 1997-10-17 | Brigham And Women's Hospital | Peptide ligands of the urokinase receptor |
| IL118003A0 (en) | 1996-04-23 | 1996-08-04 | Yeda Res & Dev | Novel vip fragments and pharmaceutical compositions comprising them |
| FR2748028B1 (fr) | 1996-04-30 | 1998-08-14 | Lab Francais Du Fractionnement | Peptides derives du facteur von willebrand et leur utilisation comme anticoagulant |
| CA2257108A1 (en) | 1996-06-07 | 1997-12-11 | Takeda Chemical Industries, Ltd. | Novel peptides and production and use thereof |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| EP0927045B1 (en) | 1996-09-10 | 2005-12-14 | The Burnham Institute | Tumor homing molecules, conjugates derived therefrom, and methods of using same |
| AU4344697A (en) * | 1996-10-04 | 1998-04-24 | Amgen, Inc. | Pharmaceutical compositions containing an mpl ligand |
| EP0934526B1 (en) | 1996-10-08 | 2003-01-08 | U-BISys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
| WO1998033812A1 (en) | 1997-02-05 | 1998-08-06 | Brigham And Women's Hospital, Inc. | Mast cell protease peptide inhibitors |
| EP0975754B2 (en) | 1997-04-16 | 2016-01-06 | Amgen Inc., | Osteoprotegerin binding proteins and their receptors |
| US6265535B1 (en) | 1997-05-30 | 2001-07-24 | The Trustees Of The University Of Pennsylvania | Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JP2001522817A (ja) | 1997-11-07 | 2001-11-20 | コンジュケム，インコーポレーテッド | オピオイドと内因性担体の新規コンジュゲート |
| AU2481399A (en) | 1998-01-29 | 1999-08-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Variant peptide ligands that selectively induce apoptosis |
| JP2002505338A (ja) | 1998-03-05 | 2002-02-19 | カイロン コーポレイション | 生物学的に活性な分子の血清半減期を増加するための方法 |
| US6235872B1 (en) | 1998-03-12 | 2001-05-22 | The Burnham Institute | Proapoptotic peptides dependence polypeptides and methods of use |
| WO1999047151A1 (en) | 1998-03-20 | 1999-09-23 | Chugai Pharmaceutical Co., Ltd. | Peptide ligands for the erythropoietin receptor |
| EP0947524A1 (en) | 1998-03-30 | 1999-10-06 | Upither B.V. | Novel peptides for the treatment of autoimmune diseases |
| WO1999051254A1 (en) | 1998-04-06 | 1999-10-14 | Advanced Immunit, Inc. | Short peptides for treatment of neurological degenerative diseases |
| DE69939036D1 (de) * | 1998-04-28 | 2008-08-14 | Serono Lab | PEG Konjugate von LHRH Analogen |
| EP0972780A1 (en) | 1998-05-18 | 2000-01-19 | Applied Research Systems ARS Holding N.V. | Il-6 antagonist peptides |
| EP1078002B1 (en) | 1998-05-22 | 2008-05-21 | Abbott Laboratories | Peptide antiangiogenic drugs |
| US5932548A (en) | 1998-06-03 | 1999-08-03 | Deghenghi; Romano | Lysine containing peptides for treatment of heart disease |
| WO2000001402A1 (en) | 1998-07-02 | 2000-01-13 | Envision Biomedical Consulting | Antiproliferative and antiviral proteins and peptides |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| AU5300299A (en) | 1998-08-21 | 2000-03-14 | Yeda Research And Development Co. Ltd. | Anti-inflammatory peptides derived from il-2 and analogues thereof |
| DK1121382T3 (da) | 1998-10-16 | 2006-11-13 | Biogen Idec Inc | Interferon-beta-fusionsproteiner og deres anvendelser |
| PT1783222E (pt) | 1998-10-23 | 2012-07-26 | Kirin Amgen Inc | Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| WO2000047740A2 (en) | 1999-02-12 | 2000-08-17 | Amgen Inc. | Tnf-related proteins |
| US6635646B1 (en) * | 1999-05-04 | 2003-10-21 | Schering Corporation | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy |
| US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| AU5943201A (en) * | 2000-05-03 | 2001-11-12 | Amgen Inc | Modified peptides as therapeutic agents |
| US6853809B2 (en) | 2001-01-30 | 2005-02-08 | Koninklijke Philips Electronics N.V. | Camera system for providing instant switching between wide angle and full resolution views of a subject |
| ATE549354T1 (de) * | 2001-05-11 | 2012-03-15 | Amgen Inc | Peptide und damit zusammenhängende an tall-1 bindende moleküle |
| RU2180233C1 (ru) | 2001-06-26 | 2002-03-10 | Общество с ограниченной ответственностью "Протеиновый контур" | Способ получения жидких лекарственных форм рекомбинантных белков |
| US7332474B2 (en) * | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
| US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| US20040247588A1 (en) | 2002-08-28 | 2004-12-09 | Johnson Robert E. | Formulations of modified antibodies and methods of making the same |
| US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| AU2003291689A1 (en) | 2002-10-31 | 2004-05-25 | Protein Design Labs, Inc. | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
| CN101287484B (zh) | 2002-12-20 | 2012-10-10 | 安姆根有限公司 | 抑制肌肉生长抑制素的结合剂 |
| WO2006010057A2 (en) | 2004-07-08 | 2006-01-26 | Amgen Inc. | Therapeutic peptides |
| EA011879B1 (ru) | 2004-09-24 | 2009-06-30 | Эмджин Инк. | МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ |
| US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| EP3035305B1 (en) | 2014-12-18 | 2016-11-16 | Axis AB | Enclosure and arrangement for recess mounting of a camera or camera head |
-
2007
- 2007-04-19 US US11/788,697 patent/US9283260B2/en active Active
- 2007-04-19 JO JOP/2007/0154A patent/JO3324B1/ar active
- 2007-04-20 MY MYPI20084070A patent/MY162816A/en unknown
- 2007-04-20 JP JP2009506615A patent/JP5432705B2/ja active Active
- 2007-04-20 EP EP12187302.0A patent/EP2594287A1/en not_active Withdrawn
- 2007-04-20 EP EP07775901.7A patent/EP2018183B1/en active Active
- 2007-04-20 CA CA2649292A patent/CA2649292C/en active Active
- 2007-04-20 ES ES07775901.7T patent/ES2599318T3/es active Active
- 2007-04-20 KR KR1020087028391A patent/KR101227278B1/ko active Active
- 2007-04-20 LT LTEP07775901.7T patent/LT2018183T/lt unknown
- 2007-04-20 EP EP12187301.2A patent/EP2594286A1/en not_active Withdrawn
- 2007-04-20 DK DK07775901.7T patent/DK2018183T3/en active
- 2007-04-20 CN CNA200780022610XA patent/CN101484185A/zh active Pending
- 2007-04-20 UA UAA200813378A patent/UA99815C2/ru unknown
- 2007-04-20 UY UY30302A patent/UY30302A1/es active IP Right Grant
- 2007-04-20 SI SI200731856A patent/SI2018183T1/sl unknown
- 2007-04-20 NZ NZ596367A patent/NZ596367A/xx unknown
- 2007-04-20 CR CR20170130A patent/CR20170130A/es unknown
- 2007-04-20 TW TW096114064A patent/TWI352598B/zh active
- 2007-04-20 SG SG2011029154A patent/SG182887A1/en unknown
- 2007-04-20 CN CN201711043851.4A patent/CN107789325A/zh active Pending
- 2007-04-20 SG SG10201501296SA patent/SG10201501296SA/en unknown
- 2007-04-20 KR KR1020127022549A patent/KR101236042B1/ko active Active
- 2007-04-20 GE GEAP200710981A patent/GEP20156253B/en unknown
- 2007-04-20 HR HRP20161653TT patent/HRP20161653T1/hr unknown
- 2007-04-20 PL PL07775901T patent/PL2018183T3/pl unknown
- 2007-04-20 WO PCT/US2007/009712 patent/WO2007124090A2/en not_active Ceased
- 2007-04-20 AR ARP070101709A patent/AR060617A1/es not_active Application Discontinuation
- 2007-04-20 EA EA201270625A patent/EA022424B1/ru not_active IP Right Cessation
- 2007-04-20 EP EP12187304.6A patent/EP2594288A1/en not_active Withdrawn
- 2007-04-20 EP EP12187297.2A patent/EP2594284A1/en not_active Withdrawn
- 2007-04-20 EA EA200802170A patent/EA017085B1/ru not_active IP Right Cessation
- 2007-04-20 MX MX2008013393A patent/MX2008013393A/es active IP Right Grant
- 2007-04-20 UA UAA201209639A patent/UA116080C2/uk unknown
- 2007-04-20 EP EP12187298.0A patent/EP2594285B1/en active Active
- 2007-04-20 AU AU2007240656A patent/AU2007240656A1/en not_active Abandoned
- 2007-04-20 RS RS20161076A patent/RS55428B1/sr unknown
- 2007-04-20 PT PT77759017T patent/PT2018183T/pt unknown
- 2007-04-20 HU HUE07775901A patent/HUE032144T2/en unknown
- 2007-04-20 BR BRPI0710508A patent/BRPI0710508B8/pt active IP Right Grant
- 2007-04-20 PE PE2007000494A patent/PE20081196A1/es active IP Right Grant
-
2008
- 2008-10-06 ZA ZA200808485A patent/ZA200808485B/xx unknown
- 2008-10-07 IL IL194653A patent/IL194653A/en active IP Right Grant
- 2008-10-07 TN TNP2008000391A patent/TNSN08391A1/en unknown
- 2008-11-14 CR CR10442A patent/CR10442A/es unknown
- 2008-11-20 NO NO20084893A patent/NO344947B1/no unknown
- 2008-11-20 MA MA31391A patent/MA30474B1/fr unknown
-
2013
- 2013-02-27 IL IL224966A patent/IL224966A/en active IP Right Grant
- 2013-09-27 JP JP2013201931A patent/JP5873854B2/ja active Active
-
2014
- 2014-06-12 CR CR20140274A patent/CR20140274A/es unknown
- 2014-12-23 PH PH12014502880A patent/PH12014502880A1/en unknown
-
2015
- 2015-10-22 JP JP2015208065A patent/JP6356106B2/ja active Active
-
2016
- 2016-01-29 US US15/011,229 patent/US10166189B2/en active Active
- 2016-09-20 CY CY20161100932T patent/CY1118038T1/el unknown
- 2016-09-29 IL IL248156A patent/IL248156B/en active IP Right Grant
-
2018
- 2018-06-12 JP JP2018111720A patent/JP6787953B2/ja active Active
-
2020
- 2020-07-30 JP JP2020128961A patent/JP2021006525A/ja active Pending
-
2022
- 2022-08-18 JP JP2022130437A patent/JP2022166219A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014040441A5 (https=) | ||
| JP2016065060A5 (https=) | ||
| JP7219258B2 (ja) | ペプチド模倣大環状分子およびその製剤 | |
| HRP20161653T1 (hr) | Liofilizirane formulacije terapeutskih peptitijela | |
| JP2009540001A5 (https=) | ||
| JP2020063241A5 (https=) | ||
| JP2009524595A5 (https=) | ||
| FI4206216T3 (fi) | Adenoassosioituneen viruksen kapsidimuunnoksia ja menetelmiä niiden käyttämiseksi | |
| JP2013525414A5 (https=) | ||
| RU2009101226A (ru) | Составы антагониста vegf, подходящие для интравитреального введения | |
| CN103874480A (zh) | 前列环素的缓释组合物 | |
| RU2010113997A (ru) | Тиролиберин для терапевтического применения | |
| RU2010114021A (ru) | Субстанция р и тиролиберин для терапевтического применения | |
| JP2019509311A5 (https=) | ||
| CN112055588B (zh) | 卡巴他赛的制剂和组合物 | |
| ES2742179T3 (es) | Composiciones farmacéuticas que comprenden agonistas del receptor de orexina-1 OX1R para el tratamiento de enfermedades inflamatorias del intestino | |
| US11654178B2 (en) | Cyclic prosaposin peptides and uses thereof | |
| JP2017510585A5 (https=) | ||
| JP2018521977A5 (https=) | ||
| WO2022192450A3 (en) | Self-assembling peptides, nanofibers, and methods of use | |
| JP2016520646A (ja) | Ｇｃ−マクロファージ活性化因子を含む組成物およびその使用 | |
| ES2864667T3 (es) | Péptidos diseñados para la modulación de la barrera de unión estrecha | |
| ES2296529B1 (es) | Composicion farmaceutica con promotores de absorcion. | |
| KR20220034053A (ko) | 재조합 단백질의 안정적인 제형 | |
| JP2022537405A (ja) | π電子対供与複素環式芳香族窒素含有化合物のコンジュゲート |